文献速递妇科

晚期卵巢癌中粟粒型与非粟粒型亚分期的预后价值

Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2017-05-08

该研究回顾2001至2015年间1008例卵巢癌、原发腹膜癌或输卵管癌初次减灭术记录,分析938例临床结局,其中436例高分期亚组用于生存分析。粟粒型病变在可评估记录中占32.7%(249/761),常伴腹水(74%),与更差的无进展生存、总生存及复发至死亡时间独立相关,IV期总生存中位差异超过30个月(log-rank p=0.002)。

要点

  • 粟粒型病变在可评估手术记录中占32.7%(249/761),74%伴腹水。
  • 粟粒型病变与更差的无进展生存、总生存及复发至死亡时间独立相关。
  • IV期患者中粟粒型病变的总生存中位差异超过30个月(log-rank p=0.002)。

核心结论

  • 粟粒型病变是可识别的手术表型,反映独特的临床轨迹,为基于疾病负荷的标准分期增加预后信息。
  • 作者认为这些发现应允许在更广泛队列中进一步回顾性研究,并促使考虑前瞻性结构化手术报告标准和治疗策略。

研究设计与样本

  • 回顾性分析2001至2015年间1008例卵巢癌、原发腹膜癌或输卵管癌初次减灭术记录,其中685份记录来自2005至2015年。
  • 临床结局数据可获取于938例患者,高分期亚组436例用于生存分析。

主要发现

  • 多数记录可评估粟粒型病变(761/938),粟粒型表型高度流行(249/761,32.7%),常伴腹水(185/249,74%)。
  • 最佳减灭率不受粟粒型病变影响,但完全切除(R0)率更差。
  • 肝、胃、脾或膀胱似乎偶有受累,而大网膜、肠系膜、肠管、腹膜和膈肌同时受累(Spearman rho>0.5)。
  • 总体而言,粟粒型病变与更差的无进展生存、总生存及复发至死亡时间独立于分期相关。
  • IV期疾病中生存效应尤其强烈,总生存中位差异超过30个月(log-rank p=0.002)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The presence of miliary disease during initial ovarian cancer debulking may reflect a distinct mode of peritoneal spread independent from size-based tumor staging and may explain variation in response to treatment and survival outcomes. To infer the prevalence, presentation and clinical implications of miliary disease we reviewed existing surgical records. METHODS: Reports were available for 1008 primary debulking surgeries for ovarian, primary peritoneal or fallopian tube cancer between 2001 and 2015 (685 reports from 2005 to 2015). Clinical outcome data was available for 938 patients. We analyzed a high-stage sub-cohort for survival (N=436). RESULTS: Most records were evaluable for miliary disease (761/938); for these, the miliary phenotype was highly prevalent (249/761, 32.7%) and often accompanied by ascites (185/249, 74%). While optimal debulking rates were unaffected by miliary disease, total resection (R0) rates were poorer. Liver, stomach, spleen or bladder appeared to be sporadically involved while the omentum, mesentery, bowel, peritoneum and diaphragm were affected simultaneously (Spearman rho>0.5). Overall, miliary disease was associated with worse progression free survival, overall survival, and time from relapse to death independent of stage. Survival effects were particularly strong for Stage IV disease where median overall survival varied by over 30months (log-rank p=0.002). CONCLUSIONS: Miliary disease is an identifiable surgical phenotype reflecting a distinct clinical trajectory that adds prognostic information to standard disease burden-based staging. These findings should permit further retrospective investigation in a wider cohort and prompt the consideration of prospective structured operative reporting standards and treatment strategies.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Eng KH, Morrell K, Starbuck K, et al. Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer. Gynecol Oncol. 2017. PMID: 28495239. doi:10.1016/j.ygyno.2017.05.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。